467-477
Original Article
Pharmacology of intracellular cytosine-arabinoside-5′-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes
U. Koehl, G. Hollatz, E. Rohrbach, K. Visschedyk and J. Cinatl, et al.
479-488
Original Article
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers
D. Ross Camidge, Mike Pemberton, Jim Growcott, Dereck Amakye and David Wilson, et al.
489-494
Original Article
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma
Byeong-Bae Park, Joon Oh Park, Hyo Rak Lee, Jeeyun Lee and Dong Wook Choi, et al.
495-501
Original Article
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA–IIIA non-small-cell lung cancer
Masafumi Kawamura, Keisuke Eguchi, Yotaro Izumi, Yasushi Yamato and Teruaki Koike, et al.
503-507
Original Article
DPYD*2A mutation: the most common mutation associated with DPD deficiency
M. W. Saif, Hany Ezzeldin, Katisha Vance, Sandra Sellers and Robert B. Diasio
509-514
Original Article
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice
Anna M. E. Bruynzeel, Suzanne Vormer-Bonne, Aalt Bast, Hans W. M. Niessen and Wim J. F. van der Vijgh
515-522
Original Article
Genetic linkage of
UGT1A7
and
UGT1A9
polymorphisms to
UGT1A1*6
is associated with reduced activity for SN-38 in Japanese patients with cancer
Ken-ichi Fujita, Yuichi Ando, Fumio Nagashima, Wataru Yamamoto and Hisashi Eodo, et al.
523-533
Original Article
Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
Mario Campone, Jeany M. Rademaker-Lakhai, Jaafar Bennouna, Stephen B. Howell and David P. Nowotnik, et al.
535-543
Original Article
Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins
Maricarmen D. Planas-Silva and Kecia N. Hamilton
545-553
Original Article
R
-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells
Elin Lindhagen, Sara Nissle, Lorenzo Leoni, Gary Elliott and Qi Chao, et al.
555-562
Original Article
Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis
Kazuaki Niikura
563-567
Original Article
Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates
Steve Y. Cho, Elizabeth Fox, Cynthia McCully, Joy Bauch and Kennan Marsh, et al.
569-579
Original Article
Open AccessInfluence of ketoconazole on the fecal and urinary disposition of docetaxel
Frederike K. Engels, Walter J. Loos, Ron A. A. Mathot, Ron H. N. van Schaik and Jaap Verweij
581-587
Original Article
Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562
Kunzhong Zhang, Jianhua Xu, Xiuwang Huang, Lixian Wu and Caixia Wen, et al.
589-600
Original Article
Preclinical antitumor activity of the oral platinum analog satraplatin
Katja Wosikowski, Lou Lamphere, Gerhard Unteregger, Volker Jung and Faith Kaplan, et al.
601-607
Original Article
Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
Lin Run Wang, Ming Zhu Huang, Guo Bing Zhang, Nong Xu and Xiu Hua Wu
609-620
Original Article
A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia
Christine Piard, Françoise Bressolle, May Fakhoury, Daolun Zhang and Karina Yacouben, et al.
621
Erratum
A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia
Christine Plard, Françoise Bressolle, May Fakhoury, Daolun Zhang and Karina Yacouben, et al.
623-624
Short Communication
Open AccessIs rectal administration an alternative route for imatinib?
Nielka P. H. van Erp, Roos L. Oostendorp, Henk-Jan Guchelaar, Jan H. M. Schellens and Hans Gelderblom